These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 2570719

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
    Andrysiak-Mamos E, Kaźmierczyk-Puchalska A, Zochowska E, Sowińska-Przepiera E, Sagan L, Kojder I, Syrenicz A.
    Pomeranian J Life Sci; 2015 Nov; 61(3):263-9. PubMed ID: 27344867
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
    Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K.
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G.
    N Engl J Med; 2003 Nov 20; 349(21):2023-33. PubMed ID: 14627787
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
    Iyer P, Molitch ME.
    Endocr Pract; 2011 Nov 20; 17(3):e55-8. PubMed ID: 21324816
    [Abstract] [Full Text] [Related]

  • 17. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Mar 20; 82(3):876-83. PubMed ID: 9062500
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas.
    Kurosaki M, Kambe A, Watanabe T, Fujii S, Ogawa T.
    Neurol Res; 2015 Apr 20; 37(4):341-6. PubMed ID: 25376133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.